Affinage

BPNT2

Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase · UniProt Q9NX62

Length
359 aa
Mass
38.7 kDa
Annotated
2026-06-09
25 papers in source corpus 9 papers cited in narrative 9 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BPNT2 (gPAPP/IMPAD1) is a Golgi-resident, magnesium-dependent, lithium-inhibited 3'-phosphatase that hydrolyzes 3'-phosphoadenosine 5'-phosphate (PAP)—the byproduct of sulfotransferase reactions—to AMP, thereby relieving product inhibition and sustaining glycosaminoglycan sulfation (PMID:18695242, PMID:22289690, PMID:29120675). This catalytic activity is essential for GAG sulfation: a catalytic-dead D108A construct fails to rescue intracellular and secreted sulfated GAGs (including chondroitin-4-sulfate) in Bpnt2-KO fibroblasts, and lithium inhibits sulfation in a BPNT2-dependent manner (PMID:34634304). Loss of this function is physiologically consequential—murine inactivation produces neonatal lethality, dwarfism, aberrant cartilage, and undersulfated chondroitin (PMID:18695242), and homozygous active-site missense mutations in humans cause chondrodysplasia with brachydactyly, joint dislocations, cleft palate, and facial dysmorphism, with disease alleles recapitulating the GAG defect in cells (PMID:21549340, PMID:34634304). Beyond its canonical sulfation role, BPNT2 drives lung cancer invasion and metastasis by enhancing Golgi-mediated secretion upstream of MMP-dependent invasion, acting through a direct interaction with the trafficking protein Syt11 to remodel Golgi morphology and the secretome, and is de-repressed during EMT upon loss of miR-200/miR-96 suppression (PMID:32753652, PMID:36170810). BPNT2-dependent control of intracellular PAP levels has additionally been implicated in a mammalian rapid tRNA decay pathway under heat stress, acting alongside Bpnt1 and Xrn1/Xrn2 (PMID:40595590).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2008 High

    Establishing where PAP, the inhibitory sulfotransferase byproduct, is cleared and why it matters answered whether a dedicated Golgi enzyme links nucleotide turnover to glycosaminoglycan sulfation.

    Evidence Mouse knockout with GAG sulfation biochemistry, subcellular localization, and in vitro lithium inhibition assay

    PMID:18695242

    Open questions at the time
    • Structural basis of catalysis and lithium sensitivity not resolved
    • Mechanism connecting undersulfation to skeletal phenotype not detailed
  2. 2011 High

    Whether BPNT2 catalytic function is required in humans was answered by linking active-site mutations to a defined skeletal disease.

    Evidence Whole-exome sequencing of affected families with active-site mutation identification, corroborated by mouse KO data

    PMID:21549340

    Open questions at the time
    • Genotype-phenotype severity correlation across mutations not established
    • Direct enzymatic deficit of patient alleles not measured in this study
  3. 2012 High

    Reconstituting the enzyme in vitro confirmed PAP-3'-phosphatase identity and quantified its kinetics, enabling its use to relieve product inhibition of sulfotransferases.

    Evidence In vitro coupled enzyme kinetics with malachite green phosphate detection and radioisotope validation

    PMID:22289690

    Open questions at the time
    • Substrate specificity relative to related phosphatases not delineated
    • In-cell kinetics not addressed
  4. 2017 Medium

    An orthogonal assay coupling PAP-to-AMP conversion confirmed AMP as the reaction product and supported sulfotransferase activity measurement.

    Evidence Enzyme-coupled bioluminescent (AMP-Glo) assay with recombinant IMPAD1

    PMID:29120675

    Open questions at the time
    • Single method, single lab
    • No new physiological insight beyond confirming product identity
  5. 2020 Medium

    Whether BPNT2 has roles beyond skeletal biology was addressed by showing it promotes lung cancer invasion via Golgi secretion upstream of MMPs.

    Evidence Gain-of-function invasion screen, in vitro/in vivo metastasis assays, MMP inhibitor epistasis

    PMID:32753652

    Open questions at the time
    • Whether catalytic activity is required for the pro-invasive effect not tested
    • Direct secreted cargoes not identified
  6. 2020 Medium

    A metabolic-signaling axis for IMPAD1 in cancer was proposed, linking AMP accumulation to AMPK-Notch1-HEY1 signaling and Complex I inhibition.

    Evidence Knockdown/overexpression with Complex I activity, ROS, signaling western blots, and ADORA1 inhibitor treatment

    PMID:32417395

    Open questions at the time
    • Non-canonical mechanism diverges from the established Golgi-PAP hydrolysis role and not independently confirmed
    • Direct mechanism by which a Golgi phosphatase inhibits mitochondrial Complex I unclear
  7. 2022 Medium

    The trafficking mechanism and upstream regulation of IMPAD1 in cancer were defined through a direct Syt11 interaction and miR-200/miR-96 control during EMT.

    Evidence miRNA target validation, Syt11 interaction assay, Golgi morphology imaging, secretome analysis, in vitro/in vivo metastasis models

    PMID:36170810

    Open questions at the time
    • Whether the Syt11 interaction depends on BPNT2 catalytic activity not resolved
    • Structural details of the BPNT2-Syt11 interface unknown
  8. 2025 Medium

    A new role for BPNT2 in RNA quality control was identified, implicating PAP-level control in heat-stress tRNA decay.

    Evidence Thumpd1 deletion in NIH/3T3 cells, tRNA decay assays under heat stress, pAp measurement, Xrn1/Xrn2 pathway epistasis

    PMID:40595590

    Open questions at the time
    • BPNT2 implicated collectively with Bpnt1, so its individual contribution is unresolved
    • Mechanistic link between PAP levels and selective tRNA degradation not detailed

Open questions

Synthesis pass · forward-looking unresolved questions
  • Whether the Golgi sulfation function, the secretory/Syt11 cancer function, and the tRNA-decay function reflect one unified PAP-clearing activity or distinct catalysis-independent roles remains unresolved.
  • No structural model of the human enzyme reported in the corpus
  • Catalytic dependence of the cancer and tRNA-decay roles not directly tested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 4
Localization
GO:0005794 Golgi apparatus 2
Pathway
R-HSA-1474244 Extracellular matrix organization 2 R-HSA-5653656 Vesicle-mediated transport 2
Partners
SYT11

Evidence

Reading pass · 9 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 gPAPP (BPNT2) is a Golgi-resident PAP 3'-phosphatase that hydrolyzes 3'-phosphoadenosine 5'-phosphate (PAP), the byproduct of sulfotransferase reactions, to AMP; its inactivation in mice leads to neonatal lethality, lung abnormalities, dwarfism with aberrant cartilage morphology, undersulfated chondroitin, and perturbations in heparan sulfate species, consistent with a role in clearing the nucleotide product of sulfotransferases within the Golgi to support glycosaminoglycan sulfation. The enzyme activity is potently inhibited by lithium in vitro. Mouse knockout model with biochemical analysis of GAG sulfation (chondroitin and heparan sulfate measurements), in vitro lithium inhibition assay, subcellular localization studies Proceedings of the National Academy of Sciences of the United States of America High 18695242
2011 Homozygous missense mutations in IMPAD1 (BPNT2) affecting residues in or adjacent to the phosphatase active site cause chondrodysplasia with brachydactyly, congenital joint dislocations, cleft palate, and facial dysmorphism in humans, consistent with impaired PAP hydrolysis and defective proteoglycan sulfation. Whole-exome sequencing of affected individuals, identification of active-site mutations, structural prediction of mutation impact; corroborated by mouse Impad1 inactivation data showing impaired proteoglycan sulfation American journal of human genetics High 21549340
2012 Recombinant gPAPP (BPNT2) was used to couple sulfotransferase reactions in vitro by releasing the 3'-phosphate from PAP, enabling determination of enzyme kinetics (Michaelis-Menten constants) and demonstrating PAP product inhibition removal for sulfotransferases. This confirms gPAPP specifically acts as a PAP 3'-phosphatase and its enzymatic rate is quantifiable for coupled assay design. In vitro enzyme kinetics assay (malachite green phosphate detection), radioisotope validation assay, coupled enzyme reaction with recombinant gPAPP Analytical biochemistry High 22289690
2021 The catalytic activity of BPNT2 is required for GAG sulfation in vitro: a catalytic-dead Bpnt2 construct (D108A) fails to rescue impaired intracellular and secreted sulfated GAGs (including chondroitin-4-sulfate) in Bpnt2-KO mouse embryonic fibroblasts. Human chondrodysplasia-causing missense mutations adjacent to the catalytic site recapitulate GAG sulfation defects in MEFs. Lithium inhibits GAG sulfation in a BPNT2-dependent manner. Catalytic-dead mutagenesis (D108A) rescue experiment in Bpnt2-KO MEFs, disease-associated missense mutation functional assay, lithium treatment of MEFs with GAG sulfation quantification The Journal of biological chemistry High 34634304
2020 IMPAD1 (BPNT2) drives lung cancer invasion and metastasis by enhancing Golgi-mediated secretion; this pro-invasive effect is suppressed by therapeutically inhibiting matrix metalloproteases (MMPs), placing IMPAD1-mediated Golgi secretion upstream of MMP-dependent invasion. Gain-of-function invasion screen, in vitro invasion assays, in vivo metastasis models, MMP inhibitor treatment Oncogene Medium 32753652
2020 IMPAD1 (BPNT2) promotes lung cancer metastasis by inhibiting mitochondrial Complex I activity, reducing mitochondrial ROS levels, and increasing intracellular AMP, which activates the AMPK-Notch1-HEY1 signaling pathway. AMP acts as an ADORA1 agonist, and ADORA1 inhibition reduces pAMPK and HEY1 expression in IMPAD1-overexpressing cells. IMPAD1 knockdown and overexpression in vitro/in vivo, mitochondrial Complex I activity assay, ROS measurement, pAMPK/Notch1/HEY1 western blotting, ADORA1 inhibitor treatment Cancer letters Medium 32417395
2022 Impad1 is a direct transcriptional target of the epithelial miRNAs miR-200 and miR~96, which suppress its expression; it is de-repressed during epithelial-to-mesenchymal transition (EMT). Impad1 modulates Golgi apparatus morphology and vesicular trafficking through a direct interaction with the trafficking protein Syt11, altering the extracellular matrix and tumor microenvironment to promote invasion and metastasis. Inhibiting either Impad1 or Syt11 disrupts the cancer cell secretome and reverses the invasive phenotype. miRNA target validation (miR-200/miR-96), co-immunoprecipitation or interaction assay with Syt11, Golgi morphology imaging, secretome analysis, in vitro invasion assays, in vivo metastasis models Cell reports Medium 36170810
2017 IMPAD1 (gPAPP/BPNT2) converts PAP to AMP in vitro, enabling coupling to the AMP-Glo bioluminescence detection system to measure sulfotransferase activities; this confirms PAP-to-AMP conversion as the specific enzymatic activity of IMPAD1. Enzyme-coupled in vitro biochemical assay using recombinant IMPAD1 to convert PAP to AMP, bioluminescent detection Assay and drug development technologies Medium 29120675
2025 BPNT2 participates in a mammalian rapid tRNA decay (mRTD) pathway for tRNA quality control under heat stress, alongside Bpnt1 and Xrn1/Xrn2 exonucleases; intracellular pAp level control by Bpnt1/Bpnt2 is required for selective degradation of tRNALeu(CAG) under heat stress. Genetic deletion of Thumpd1 in NIH/3T3 cells, tRNA decay assays under heat stress, measurement of pAp levels, pathway epistasis with Xrn1/Xrn2 Nature communications Medium 40595590

Source papers

Stage 0 corpus · 25 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. American journal of human genetics 71 21549340
2021 Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects. Life sciences 70 34043989
2008 A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation. Proceedings of the National Academy of Sciences of the United States of America 60 18695242
2014 Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas. Oncogenesis 59 24662924
2020 IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion. Oncogene 35 32753652
2017 Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions. Assay and drug development technologies 23 29120675
2023 LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing. Clinical and translational medicine 21 36650118
2013 Role for cytoplasmic nucleotide hydrolysis in hepatic function and protein synthesis. Proceedings of the National Academy of Sciences of the United States of America 20 23479625
2020 IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Notch1-HEY1 pathway. Cancer letters 19 32417395
2018 Glycerophosphatidylcholine PC(36:1) absence and 3'-phosphoadenylate (pAp) accumulation are hallmarks of the human glioma metabolome. Scientific reports 13 30283018
2012 Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays. Analytical biochemistry 13 22289690
2022 Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell reports 10 36170810
2022 An imputation-based genome-wide association study for growth and fatness traits in Sujiang pigs. Animal : an international journal of animal bioscience 8 35872387
2021 Sulfation of glycosaminoglycans depends on the catalytic activity of lithium-inhibited phosphatase BPNT2 in vitro. The Journal of biological chemistry 8 34634304
2019 Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients. G3 (Bethesda, Md.) 8 30914425
2013 Tissue-specific regulation of 3'-nucleotide hydrolysis and nucleolar architecture. Advances in biological regulation 7 24309248
2023 Genetic testing and diagnostic strategies of fetal skeletal dysplasia: a preliminary study in Wuhan, China. Orphanet journal of rare diseases 6 37875969
2019 Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice. PloS one 6 30865697
2024 Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation. International journal of medical sciences 4 38464823
2025 Mammalian tRNA acetylation determines translation efficiency and tRNA quality control. Nature communications 3 40595590
2025 Systematic Mendelian randomization of the human plasma proteome to identify therapeutic targets linking aging and frailty to perioperative delirium. Journal of affective disorders 1 40451486
2025 Selective sweeps for mutations increasing height impede identification of causative mutations for fertility and other correlated traits in cattle. Genetics, selection, evolution : GSE 1 41057762
2022 Fetal presentation of chondrodysplasia with joint dislocations, GPAPP type, caused by novel biallelic IMPAD1 variants. American journal of medical genetics. Part A 1 34989141
2026 Genetic Skeletal Disorders with Defects in Glycosaminoglycan Biosynthesis. Molecular syndromology 0 42094029
2025 MicroRNA analysis of porcine muscle tissue involved in phosphoinositol metabolism. Frontiers in veterinary science 0 40777826

Missed literature

Know a paper Affinage missed for BPNT2? Flag it for the maintainers and the community.

No submissions yet.